温馨提醒:文章旨在传递疾病知识,不作为诊疗方案推荐及医疗依据。
责任编辑:觅健丸时
参考资料:
[1] Howlader, N. et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J. Natl Cancer Inst. 106, dju055 (2014).
[2] Stephen R D Johnston et al. Lancet Oncol. 2023 Jan;24(1):77-90.
[3] Sheffield KM, et al. Future Oncol 2022; 18(21):2667-2682.
[4] ohnston SRD, Harbeck N, Hegg R, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020 Sep 20:JCO2002514. doi: 10.1200/JCO.20.02514. Epub ahead of print. PMID: 32954927.
[5] Rastogi P. Presented at: SABCS 2020. Abstract GS1-01.
[6] Verzenio. Prescribing information. Lilly USA, LLC.
[7]葛睿, 王碧芸, 江泽飞, 等. 乳腺癌CDK4/6抑制剂相关性不良反应管理共识[J]. 中华肿瘤杂志, 2022, 44(12):1296-1304.
[8] Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial. 2023 ASCO. LBA 500.
[9] Larissa A. Korde, MD; Mark R. Somerfield, PhD; Lisa A. Carey, MD et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline, JCO 2020.
[10] Erica L Mayer, MD; Amylou C Dueck, PhD; Prof Miguel Martin, MD et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study, Lancet Oncol 2021.